| Authors: |
Surana R; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Morgado M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Somasundaram A; Division of Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Bockorny B; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA., Weekes CD; Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA., Coleman EC; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Bird A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Wang J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Williams HL; Department of Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Zheng H; Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA., Brais LK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Saxena N; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Graham C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Ritterband L; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Sawin M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Peters ML; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA., Whooley P; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA., Bullock A; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA., Zerillo J; Department of Medical Oncology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA., Sanoff HK; Division of Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Clark JW; Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA., Parikh AR; Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA., Yurgelun MB; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Patel AK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Mayer RJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Enzinger P; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Rubinson DA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., McCleary NJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Enzinger A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Slater S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Biller LH; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Abrams TA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Huffman BM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Singh H; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Raghavan S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Mancias JD; Department of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Bryant KL; Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Nowak JO; Department of Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Der CJ; Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Perez K; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA. |
